Role of Efflux Pumps on Antimicrobial Resistance in Pseudomonas aeruginosa
- PMID: 36555423
- PMCID: PMC9779380
- DOI: 10.3390/ijms232415779
Role of Efflux Pumps on Antimicrobial Resistance in Pseudomonas aeruginosa
Abstract
Antimicrobial resistance is an old and silent pandemic. Resistant organisms emerge in parallel with new antibiotics, leading to a major global public health crisis over time. Antibiotic resistance may be due to different mechanisms and against different classes of drugs. These mechanisms are usually found in the same organism, giving rise to multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria. One resistance mechanism that is closely associated with the emergence of MDR and XDR bacteria is the efflux of drugs since the same pump can transport different classes of drugs. In Gram-negative bacteria, efflux pumps are present in two configurations: a transmembrane protein anchored in the inner membrane and a complex formed by three proteins. The tripartite complex has a transmembrane protein present in the inner membrane, a periplasmic protein, and a porin associated with the outer membrane. In Pseudomonas aeruginosa, one of the main pathogens associated with respiratory tract infections, four main sets of efflux pumps have been associated with antibiotic resistance: MexAB-OprM, MexXY, MexCD-OprJ, and MexEF-OprN. In this review, the function, structure, and regulation of these efflux pumps in P. aeruginosa and their actions as resistance mechanisms are discussed. Finally, a brief discussion on the potential of efflux pumps in P. aeruginosa as a target for new drugs is presented.
Keywords: Pseudomonas aeruginosa; antimicrobial resistance; efflux pumps.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa.J Bacteriol. 2005 Feb;187(4):1384-91. doi: 10.1128/JB.187.4.1384-1391.2005. J Bacteriol. 2005. PMID: 15687203 Free PMC article.
-
Metabolic Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant Pseudomonas aeruginosa Mutants Overexpressing Efflux Pumps.mBio. 2017 Jul 25;8(4):e00500-17. doi: 10.1128/mBio.00500-17. mBio. 2017. PMID: 28743808 Free PMC article.
-
Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.Antimicrob Agents Chemother. 2003 Mar;47(3):972-8. doi: 10.1128/AAC.47.3.972-978.2003. Antimicrob Agents Chemother. 2003. PMID: 12604529 Free PMC article.
-
Antibiotic influx and efflux in Pseudomonas aeruginosa: Regulation and therapeutic implications.Microb Biotechnol. 2024 May;17(5):e14487. doi: 10.1111/1751-7915.14487. Microb Biotechnol. 2024. PMID: 38801351 Free PMC article. Review.
-
Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms.J Mol Microbiol Biotechnol. 2001 Apr;3(2):255-64. J Mol Microbiol Biotechnol. 2001. PMID: 11321581 Review.
Cited by
-
Microbiological and molecular studies on a multidrug-resistant Pseudomonas aeruginosa from a liver transplant patient with urinary tract infection in Egypt.BMC Microbiol. 2024 May 27;24(1):184. doi: 10.1186/s12866-024-03318-0. BMC Microbiol. 2024. PMID: 38802754 Free PMC article.
-
Repurposing approved drugs as potential efflux pump inhibitors in multidrug-resistant Pseudomonas aeruginosa.Future Microbiol. 2024;19(6):495-508. doi: 10.2217/fmb-2023-0208. Epub 2024 Apr 17. Future Microbiol. 2024. PMID: 38629920 Free PMC article.
-
Antibiotic-Resistant Pseudomonas aeruginosa: Current Challenges and Emerging Alternative Therapies.Microorganisms. 2025 Apr 16;13(4):913. doi: 10.3390/microorganisms13040913. Microorganisms. 2025. PMID: 40284749 Free PMC article. Review.
-
The FinO/ProQ-like protein PA2582 impacts antimicrobial resistance in Pseudomonas aeruginosa.Front Microbiol. 2024 Jun 26;15:1422742. doi: 10.3389/fmicb.2024.1422742. eCollection 2024. Front Microbiol. 2024. PMID: 39011145 Free PMC article.
-
Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins Against Klebsiella pneumoniae and Pseudomonas aeruginosa.Microorganisms. 2025 May 27;13(6):1227. doi: 10.3390/microorganisms13061227. Microorganisms. 2025. PMID: 40572115 Free PMC article.
References
-
- Fleming A. On the Antibacterial Action of Cultures of a Penicillium, with Special Reference to Their Use in the Isolation of B. Influenzæ. Br. J. Exp. Pathol. 1929;10:226–236. doi: 10.1093/clinids/2.1.129. - DOI
-
- World Health Organization . Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2021. World Health Organization; Geneva, Switzerland: 2021. p. 180.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical